Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson ÓG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Åsberg A, Frandsen TL, Marquart HV, Madsen HO, Norén-Nyström U, Schmiegelow K. Toft N, et al. Among authors: madsen ho. Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18. Leukemia. 2018. PMID: 28819280
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Flaegstad T, Heyman M, Jonsson OG, Harila-Saari A, Madsen HO, Porwit A, Schmiegelow K, Söderhäll S, Wesenberg F, Vettenranta K, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: madsen ho. Leuk Res. 2011 Apr;35(4):472-8. doi: 10.1016/j.leukres.2010.09.001. Epub 2010 Oct 18. Leuk Res. 2011. PMID: 20961616
DNA Methylation Adds Prognostic Value to Minimal Residual Disease Status in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Borssén M, Haider Z, Landfors M, Norén-Nyström U, Schmiegelow K, Åsberg AE, Kanerva J, Madsen HO, Marquart H, Heyman M, Hultdin M, Roos G, Forestier E, Degerman S. Borssén M, et al. Among authors: madsen ho. Pediatr Blood Cancer. 2016 Jul;63(7):1185-92. doi: 10.1002/pbc.25958. Epub 2016 Feb 29. Pediatr Blood Cancer. 2016. PMID: 26928953 Clinical Trial.
Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
Ifversen M, Turkiewicz D, Marquart HV, Winiarski J, Buechner J, Mellgren K, Arvidson J, Rascon J, Körgvee LT, Madsen HO, Abrahamsson J, Lund B, Jonsson OG, Heilmann C, Heyman M, Schmiegelow K, Vettenranta K. Ifversen M, et al. Among authors: madsen ho. Br J Haematol. 2019 Mar;184(6):982-993. doi: 10.1111/bjh.15761. Epub 2019 Jan 24. Br J Haematol. 2019. PMID: 30680711 Free article.
Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype-genotype study.
Helenius M, Vaitkeviciene G, Abrahamsson J, Jonsson ÓG, Lund B, Harila-Saari A, Vettenranta K, Mikkel S, Stanulla M, Lopez-Lopez E, Waanders E, Madsen HO, Marquart HV, Modvig S, Gupta R, Schmiegelow K, Nielsen RL. Helenius M, et al. Among authors: madsen ho. Pediatr Blood Cancer. 2022 Jun;69(6):e29582. doi: 10.1002/pbc.29582. Epub 2022 Mar 22. Pediatr Blood Cancer. 2022. PMID: 35316565
Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients.
Wesołowska-Andersen A, Borst L, Dalgaard MD, Yadav R, Rasmussen KK, Wehner PS, Rasmussen M, Ørntoft TF, Nordentoft I, Koehler R, Bartram CR, Schrappe M, Sicheritz-Ponten T, Gautier L, Marquart H, Madsen HO, Brunak S, Stanulla M, Gupta R, Schmiegelow K. Wesołowska-Andersen A, et al. Among authors: madsen ho. Leukemia. 2015 Feb;29(2):297-303. doi: 10.1038/leu.2014.205. Epub 2014 Jul 3. Leukemia. 2015. PMID: 24990611 Free PMC article.
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: madsen ho. Leukemia. 2019 Jun;33(6):1324-1336. doi: 10.1038/s41375-018-0307-6. Epub 2018 Dec 14. Leukemia. 2019. PMID: 30552401
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: madsen ho. Leukemia. 2020 Jun;34(6):1719-1720. doi: 10.1038/s41375-019-0672-9. Leukemia. 2020. PMID: 31822778
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
Modvig S, Hallböök H, Madsen HO, Siitonen S, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Matuzeviciene R, Stoskus M, Marincevic M, Lilleorg A, Ehinger M, Norén-Nystrøm U, Toft N, Taskinen M, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Porwit A, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: madsen ho. Leukemia. 2021 Jul;35(7):1894-1906. doi: 10.1038/s41375-020-01100-5. Epub 2020 Dec 14. Leukemia. 2021. PMID: 33318611 Free PMC article.
231 results